Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentations in Non-Small Cell Lung Cancer by Na, Im Il et al.
International Scholarly Research Network
ISRN Oncology
Volume 2011, Article ID 756265, 6 pages
doi:10.5402/2011/756265
Research Article
Association of Epidermal Growth Factor Receptor Mutations with
Metastatic Presentations in Non-Small CellLung Cancer
Im Il Na,1 Jong Heon Park,2 DuHwanChoe,2 Jin Kyung Lee,3 andJaeSooKoh4
1Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences,
215-4, Gongneung-dong, Nowon-gu, Seoul 139-706, Republic of Korea
2Department of Radiology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul 139-706,
Republic of Korea
3Department of Laboratory Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences,
Seoul 139-706, Republic of Korea
4Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul 139-706,
Republic of Korea
C o r r e s p o n d e n c es h o u l db ea d d r e s s e dt oI mI lN a ,hmona@kcch.re.kr
Received 15 February 2011; Accepted 24 March 2011
Academic Editors: B. Fang and L. Mutti
Copyright © 2011 Im Il Na et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We performed this retrospective study to assess the association of epidermal growth factor receptor (EGFR) with metastatic
presentations in advanced non-small cell lung cancer (NSCLC). The data from 125 patients with stage III or IV NSCLC were
analyzed. We detected EGFR mutations in 36 NSCLC patients. EGFR mutations were predominant in never-smokers (P<. 001),
patients with adenocarcinomas (P<. 001), and female patients (P<. 001). When the metastatic sites were analyzed, pleural
metastases were associated with a high incidence of EGFR mutations (P = .028). Particularly, pleural metastases with minimal
eﬀusion (PMME) were associated with EGFR mutational status (P = .001). Patients with N3 lesions were less likely to harbor
EGFR mutations (P = .033). On multivariate analysis, N3 lesions (P = .017) and PMME (P<. 001) remained signiﬁcant factors
for EGFR mutations. EGFR mutations may be associated with diﬀerent presentations of pleural and N3 nodal metastases.
1.Introduction
Intermsofnewcases,lungcancerisoneofthemostcommon
cancers worldwide [1, 2], and the most frequent type is
non-small cell lung cancer (NSCLC). Patients with early
stageNSCLChavelong-termsurvivalwithsurgicalresection;
however,themajorityofpatientspresentwithadvancedstage
NSCLC (III or IV) have a dismal prognosis with disease
progression [3, 4].
To improve clinical outcome in patients with NSCLC,
tyrosine kinase inhibitors (TKIs), such as geﬁtinib or erlo-
tinib, were introduced. With respect to TKI responsiveness,
recent molecular studies have shown that mutations in the
epidermal growth factor receptor (EGFR) can predict out-
comes [5]. It has been demonstrated that EGFR mutations
are frequently found in females, patients with adenocar-
cinomas, and never-smokers [6, 7]. Researchers have also
reported that most EGFR mutations consist of exon 19
deletions and exon 21 L858R substitutions [6, 7].
Metastases to the pleura and lymph nodes at the time
of presentation are common and confer a poor prognosis
in patients with stage III or IV NSCLC [8]. In patients
with adenocarcinomas, the predominant histology of EGFR-
mutant tumors [6], pleural metastases are a frequent ﬁnding
[9]. Recently, genetic studies of other solid tumors have
suggested that there are preferential metastatic sites accord-
ing to gene expression [10, 11]. An animal model of lung
cancer has also shown diﬀerent patterns of pleural and
nodal metastases according to genetic expression related
to angiogenesis and lymphangiogenesis [12]. Interestingly,
a high detection rate of EGFR mutations (approximately
70%) has been reported in malignant pleural eﬀusions of
pulmonary adenocarcinoma [13]. However, associations
between metastatic presentations and EGFR mutations have
not been fully evaluated in patients with advanced NSCLC.
Clinicalfeaturesmayhelpphysiciansselectpatientslikely
to beneﬁt from treatment with TKIs, while genetic tests2 ISRN Oncology
have several limitations, such as insuﬃcient material and a
time-consuming process. In addition, evaluation of diﬀerent
clinical presentations according to EGFR mutations may
add new insight for further therapy. We performed this
retrospective study to identify possible associations between
metastatic presentations and EGFR mutations.
2.MaterialsandMethods
2.1. Patients. We initially identiﬁed patients who had docu-
mented results for EGFR mutational status from the NSCLC
pathology database of the Korea Cancer Center Hospital
(Seoul, Republic of Korea) between March 2007 and June
2010. Informed consent for genetic tests was also required.
Among the initially identiﬁed patients, those with stage III
or stage IV NSCLC were included using new criteria [8].
Four patients with histories of other malignancies, except
thyroid cancer, were excluded. One hundred twenty-ﬁve
patientswereincluded.TandNstagesweredecidedbasedon
ﬁndings of computed tomography (CT). Pleural metastases
were considered positive based on cytologic examinations
or CT scans revealing the following criteria: (1) massive
pleural eﬀusion with or without pleural thickening, (2)
circumferential thickening, (3) focal and/or diﬀuse nodu-
larity of the pleura, (4) parietal pleural thickening >1cm,
and (5) mediastinal pleural thickening [14–16]. Pleural
metastases were categorized into pleural metastases with
minimal eﬀusion (PMME) and non-PMME. We deﬁned
PMME as pleural metastases without eﬀusion or those not
detected on chest radiography but only on CT (Figure 1).
Two thoracic radiologists (DHC and JHP) reviewed the CT
images.DecisionsonCTﬁndingswerereachedbyconsensus.
Regional lymph nodes larger than 1cm in the short axis on
transaxial CT images were considered positive. Metastases to
brain and bone were determined using previously described
criteria [17]. The Institutional Review Board of the Korea
Cancer Center Hospital approved this study.
2.2. EGFR Genotyping. Genomic DNA was extracted from
114 paraﬃn-embedded tissues, as described previously in
[18]. In eleven patients, methanol-ﬁxed cytologic specimens
were used for DNA extraction [19]. The EGFR mutations
of 52 patients were analyzed by direct sequencing [18].
Pyrosequencing was performed in 73 patients as follows:
DNA was ampliﬁed with PCR primer sets, and one strand
of each set was bound to biotin at the 5  end (primer
sequences are available upon request). The PCR procedure
was carried out in a total volume of 50μL containing 5μL
of the DNA (2ng/μL), 1μLo fe a c hp r i m e r( 1 0 μMpmol),
4μLo fM g C l 2,5 μL of 10x PCR buﬀer, 2.5μLo fd N T P
(2.5mM), 0.3μL of TaqGold DNA polymerase, and 31.2μL
of H2O. The PCR conditions consisted of initial denaturing
at 95◦C for 5min, 45 cycles at 95◦C for 15s, 54◦Cf o r
30s, and 72◦Cf o r1 5 s ,a n daﬁ n a le x t e n s i o na t7 2 ◦Cf o r
5min. The PCR products were analyzed by electrophoresis
in a 2% agarose gel to conﬁrm successful ampliﬁcation.
The other 40μL of PCR product was bound to streptavidin
beads (GE Healthcare, Buckinghamshire, UK), puriﬁed,
∗
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Figure 1: Pleural metastases with large amount of eﬀusion (∗)
and diﬀuse pleural thickening (arrows) in a patient with wild-type
EGFR. (a) Focal nodularity (arrows) without pleural eﬀusion in a
patient with L858R substitution in exon 21 (b).
washed, and denatured with 0.2mol/L NaOH solution.
Then, 0.3μmol/L pyrosequencing primer was annealed to
the puriﬁed single-stranded PCR product, and sequencing
was done on a PyroMark ID system (Biotage, Sweden)
following the manufacturer’s instructions. The presence of
EGFR mutations was determined by mutations in exons 18,
19, and 21.
2.3. Statistical Analysis. Univariate analysis of categorical
variables was performed using Pearson’s χ2 test or Fisher’s
exact test. Multivariate logistic regression analysis with
stepwise forward selection was performed to identify inde-
pendent predictors for EGFR mutations. The signiﬁcance of
variables in the ﬁnal model was evaluated after controllingISRN Oncology 3
Table 1: Patient characteristics (n = 125).
Characteristic Number of patients (%)
Age (years)
Median 63 (range, 28–83)
Gender
Male 87 (70)
Female 38 (30)
Smoking history
Never 45 (36)
Ever 80 (64)
Histopathology
ADC∗ 81 (65)
Other 44 (35)
Tumor size (cm)
Median 4.2 (range, 1.0–10.0)
Ts t a g e
T1-2 84 (67)
T3-4 41 (33)
Ns t a g e
N0–2 86 (69)
N3 39 (31)
MS t a g e
M0 43 (34)
M1 82 (66)
Metastatic sites
Pleura 26 (21)
PMME 13
Lung 38 (30)
Brain (n = 122) 23 (19)
Bone (n = 124) 37 (30)
Liver 7 (6)
Other† 14 (11)
Abbreviations: ADC, adenocarcinoma; PMME, pleural metastases with
minimal eﬀusion.
∗Two bronchioloalveolar carcinomas.
†Including nine adrenal gland metastases.
f o rg e n d e re ﬀect. Odds ratios (ORs) and the 95% conﬁdence
intervals (CIs) were determined. Stata (version 9.0; Stata
Corp., College Station, Tex, USA) was used for statistical
analyses.
3. Results
3.1.DescriptiveData. Thepatientcharacteristicsaresumma-
rizedinTable 1.Themedianagewas63years,and70%ofthe
patients were men. The primary tumors ranged 1.0–10.0cm
in size (median, 4.2cm). Sixty-ﬁve percent of patients had
adenocarcinomas, and 46 patients (36%) had never smoked.
The proportion of patients with stage III and IV NSCLC
was 34% and 66%, respectively. Twenty-six patients (20%)
presented with pleural metastases. Thirty-nine patients had
stage N3 NSCLC.
3.2.ClinicalFeaturesAssociatedwithEGFRMutations. EGFR
mutations were detected in 36 patients (29%), as follows:
G719A (3 patients), exon 19 deletions (24 patients), and
an L858R substitution in exon 21 (9 patients). Associations
between clinical features and EGFR mutations were evalu-
ated using univariate analysis; the results are listed in Table 2.
Adenocarcinomas (P<. 001), female gender (P<. 001),
and never-smokers (P<. 001) were positively related with
the presence of EGFR mutations. Tumor size, dichotomized
based on the median value, was not linked with EGFR
mutations (P = .367). Tumors with N3 nodal stage were
less likely to harbor EGFR mutations (P = .033), whereas T
stage was not related with EGFR mutations (P = .616). The
incidence of EGFR mutations in stage IV was more common
than that in stage III (P = .037). When distant metastatic
sites (pleura, lung, liver, bone, and others) were analyzed
according to EGFR mutations, pleural metastases alone
were signiﬁcantly associated with a high incidence of EGFR
mutations (P = .028). Further logistic regression analysis for
the patterns of pleural metastases revealed that patients with
PMMEshowedahigherprobabilityofEGFRmutations(OR,
7.7; 95% CI, 2.2–26.8; P = .001) than those without pleural
metastases, whereas patients with non-PMME did not (OR,
0.6; 95% CI, 0.1–2.7; P = .472). On multivariate analysis,
N3nodalstatusandPMME,alongwithadenocarcinomaand
a history of never-smoking, remained signiﬁcant factors for
EGFR mutations (Table 2). However, stage was removed as a
redundant variable, and gender did not maintain a statistical
signiﬁcance in the ﬁnal model (P = .805).
3.3. Clinical Features and TKI Responsiveness. Until July
2010,amongpatientswhoreceivedTKImonotherapy,tumor
response, as based on CT, was evaluable in 44 patients. When
tumor response was classiﬁed using the Response Evaluation
Criteria in Solid Tumors criteria [20], a partial response
was noted in 21 patients. The response rate of 21 patients
with EGFR mutations was greater than that of 23 patients
with wild type (90% versus 9%, resp.; P<. 001). Seventeen
patients with N3 stage showed a tendency toward a lower
response rate than 27 patients with N0–2 stage (29% versus
59%, resp.; P = .069). Although the response rate of 6
patients with PMME was higher than that of 38 patients
without PMME (67% versus 45%, resp.), the diﬀerence was
not signiﬁcant (P = .403).
4. Discussion
The aim of the current study was to assess the association
between metastatic presentations and EGFR mutations in
stageIII-IVNSCLCpatients.Basedonourdata,patientswith
advanced nodal stagehad a low probability of the presence of
EGFRmutationscomparedwiththosewithearlynodalstage.
In addition, we observed diﬀerent presentations of pleural
metastases according to EGFR mutational status.
In this study, we focused on metastatic presentations
and their associations with EGFR mutations. As in previous
studies, the incidence of EGFR mutations was also within
the range previously reported in [6, 7]. The predominance4 ISRN Oncology
Table 2: Relationship between clinical factors and EGFR mutations.
Characteristic Number of patients with EGFR mutations (%) P OR in multivariate analysis (95% CI) P
Age, years .690 NI
≤63 18 (27)
>63 18 (31)
Gender <.001 .805
Male 15 (17) Reference
Female 21 (55) 0.8 (0.1–4.8)
Smoking history <.001 .020
Yes 12 (15) Reference
Never 24 (53) 7.7 (1.4–42.8)
Histology <.001 .005
ADC 32 (40) 9.4 (2.0–41.5)
Others 4 (9) Reference
Tumor size .367 NI
Small (≤4.2) 21 (32)
Large (>4.2) 15 (25)
T stage .616 NI
T1-2 23 (27)
T3-4 13 (32)
N stage .033 .017
N0–2 30 (35) Reference
N3 6 (15) 0.2 (0.0–0.7)
M stage .037 NI
M0 7 (16)
M1 29 (35)
Metastases to pleura .001
PMME 10 (71) 24.2 (4.1<) <.001
Non-PMME 2 (15) 0.8 (0.1–5.2) .783
No 24 (24) Reference
Metastases to lung .082 NI
No 21 (24)
Yes 15 (39)
Metastases to brain .075 NI
No 24 (24)
Yes 10 (43)
Metastases to bone .121 NI
No 21 (24)
Yes 14 (39)
Metastases to liver .410 NI
No 33 (28)
Yes 3 (43)
Metastases to other sites .347 NI
No 34 (31)
Yes 2 (14)
A b b r e v i a t i o n sa si nTable 1.
of EGFR mutations in never-smokers, patients with adeno-
carcinomas, and females was also observed [6]. Unlike prior
studies, which evaluated the imaging ﬁndings of primary
tumors[21,22],ourdatasuggestedalinkbetweenmetastatic
sites and EGFR mutations. Although a prior study reported
a high incidence of EGFR mutations in patients with brain
metastases, the study was limited by a small sample size
[23]. In our data, the incidence of EGFR mutations was not
statistically related to metastatic sites, such as the brain and
bone (Table 2). Of note, like brain and bone metastatic sites,
stage alone did not maintain a signiﬁcant variable regarding
EGFR mutational status in the ﬁnal model, whereas PMMEISRN Oncology 5
did. Additionally, studies suggest that EGFR mutations may
occur as early events in contrast to EGFR ampliﬁcation
[24, 25]. Thus, preferential sites of EGFR-mutant tumors,
rather than tumor extent, were suggested in this study.
The current study may oﬀer additional insight into the
spread of EGFR-mutant tumors and be helpful in the devel-
opmentofeﬀectivetherapies.Understandingthemechanism
of tumor spread may be essential in establishing eﬀective
treatment regimens. It is well known that EGFR mutations
are predominantly found in patients with adenocarcinoma,
history of never-smoking, and female gender [6, 7]. In this
study, a strong association of EGFR mutational status with
nodal stage and pattern of pleural metastases was suggested.
Although the more common presentation of pleural metas-
tases in patients with EGFR mutations was suggested in
other genetic studies regarding pleural eﬀusion [26, 27],
we observed an interesting ﬁnding of the predominant pre-
sentation of PMME in EGFR-mutant tumors. Despite rare
molecular data to support this ﬁnding, it is partly consistent
with results of a Korean study suggesting unexpected pleural
metastasesatthoracotomyinfemales[28],oneofstrongpre-
dictorsforEGFRmutations[6,7].Althoughitcanbethecase
by chance and has limitation of small sample size, we believe
that this ﬁnding is worthy of further molecular research.
The signiﬁcance of metastatic patterns also warrants further
extensive studies regarding selection of beneﬁcial patients,
particularly when genetic information is unavailable.
Although the underlying mechanisms are not fully
understood, vascular endothelial growth factor (VEGF) may
contribute to pleural metastases with accelerating angiogen-
esis or lymphangiogenesis [29–31]. Laboratory ﬁndings have
shown that activation of EGFR signaling may lead to VEGF
expression in cancer cells [32, 33]. Interestingly, in addition
to pleural metastases, diﬀerent patterns of nodal metastases
according to expression of the VEGF subfamily have been
suggested in an animal model of lung cancer [12]. Theo-
retically, metastatic sites could diﬀer by the expressed VEGF
subfamily. Further molecular studies need to be conducted.
Becausemetastasestonodalstageweredeterminedbased
on CT scans, one can question the diagnostic accuracy [34].
In clinical practice, it appears that CT alone may be a
useful tool for determining the extent of disease, especially in
patients with distant metastases. However, positron emission
tomography, despite limited availability, warrants particular
consideration because of its high accuracy of nodal stage
and associations with TKI responsiveness [34, 35]. Further
research needs to be conducted to understand the character-
istics of patients with EGFR mutations.
The results of this study had suggested diﬀerent patterns
of pleura and mediastinal nodal metastases according to
the presence of EGFR mutations in patients with advanced
NSCLC. This ﬁnding adds new insight into understanding
thespreadofEGFR-mutanttumors.However,thisretrospec-
tive study needs validation with further molecular ﬁndings.
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